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ABSTRACT

INTRODUCTION

We report alterations to the murine leukemia virus
(MLV) integrase (IN) protein that successfully result
in decreasing its integration frequency at transcription start sites and CpG islands, thereby reducing the
potential for insertional activation. The host bromo
and extraterminal (BET) proteins Brd2, 3 and 4 interact with the MLV IN protein primarily through the
BET protein ET domain. Using solution NMR, protein
interaction studies, and next generation sequencing,
we show that the C-terminal tail peptide region of MLV
IN is important for the interaction with BET proteins
and that disruption of this interaction through truncation mutations affects the global targeting profile
of MLV vectors. The use of the unstructured tails of
gammaretroviral INs to direct association with complexes at active promoters parallels that used by histones and RNA polymerase II. Viruses bearing MLV IN
C-terminal truncations can provide new avenues to
improve the safety profile of gammaretroviral vectors
for human gene therapy.

Retroviruses have been used as an important tool in developing gene therapy vectors. Their ability to stably integrate
genetic information into the host genome has enabled the
exploitation of these viruses for many gene delivery applications. Gammaretroviral vectors have been used successfully to rectify defects of SCID-X1 and other diseases (1).
However, despite the efficiency in gene delivery, insertional
mutagenesis can result in clonal expansion of cells bearing
specific integrants (2), associated with the preferential integration of murine leukemia virus (MLV) vectors upstream
of transcription start sites (TSS) and CpG islands near promoter regions (3). This complicates their use in gene therapy.
In the retroviral replication cycle, the viral reverse transcriptase enzyme converts the single-stranded RNA viral
genome into double-stranded DNA, which is associated
within a preintegration complex (PIC). MLV requires cells
to undergo mitosis. The viral p12 protein, which is part of
the PIC, is responsible for tethering the viral genome to
the host mitotic chromatin (4–5). However, the p12 protein
does not mediate targeting of the viral PIC toward genomic
hotspots for retroviral integration such as TSS and CpG islands (5). The viral integrase (IN), upon entry into the host
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nucleus, mediates the integration of the viral DNA into the
host genome (6). The viral IN protein is the primary viral
determinant for target-site selection (7).
It has recently been shown that the host bromo and extraterminal (BET) domain proteins Brd 2, 3 and 4 bind
the viral IN protein through their conserved ET domain
(8–10). The down regulation of BET proteins with siRNAs (8–9) as well as treatment with a small molecule inhibitor JQ1, which selectively impairs BET protein association with chromatin, showed decrease in preferential integration targeting at TSS and CpG islands (8–10). In the
presence of LEDGF-BET protein chimeras (10), integration can be shifted toward LEDGF binding sites. In vitro
interaction studies and coimmunoprecipitation of overexpressed MLV IN in mammalian cells have mapped the BET
binding sites to different domains of MLV IN including the
catalytic core domain (CCD) (9), the C-terminal domain
(CTD) (8,10) and the IN C-terminus (10).
In this report, we demonstrate that the C-terminal
polypeptide segment of the viral IN protein, which we refer
to as the tail peptide (TP), is a key determinant in mediating
the interaction of the viral IN protein with the ET domain
of the BET proteins. This interaction provides a structural
basis for global in vivo integration-site preferences. MLV
virus bearing IN lacking this C-terminal 28-residue TP are
viable in tissue culture (11–12) and in vitro (13–14). Hence,
deletion of the TP does not disrupt the catalytic properties
of IN. MLV IN lacking the TP lose their interaction with
BET proteins, thus presenting a direct mechanism to alter
target-site utilization. Virus bearing IN lacking the TP, or
with it replaced with other peptides, exhibits markedly diminished viral integrations in mammalian cells near TSS,
CpG islands, and known BET binding sites.
MATERIAL AND METHODS
Plasmid constructs
IN1–385 XN (previously named IN in6215a (11)) is an infectious M-MLV clone in which a NotI restriction site was
inserted at an XbaI site and results in premature truncation of the IN protein at IN position 385. Insertions into
the M-MLV infectious clone expressing IN in6215a ((11);
IN1–385 XN ) were performed at the NotI site using oligonucleotides, as described in the Supplementary Data. The
MLV IN CTD was expressed in the bacterial pET15 NESG
vector (15) at the NdeI and BamHI sites. Details of the glutathione S-transferase (GST)-IN and Brd3 ET constructs
along with the cloning protocols are provided in the Supplementary Data.
Protein purification for NMR studies
Protein expression and purification from the pET-based
construct for MLV IN CTD was performed as previously
described (15–18) with the following modifications: protein
expression was induced with 1 mM IPTG at 17◦ C for 25
h. Induction was carried out in MJ9 media (17–18) in the
presence of either 15 N-labeled ammonium chloride or 15 N
ammonium chloride plus uniformly 13 C-enriched glucose.
Following Ni-NTA resin purification (Qiagen) as per manufacturer’s instructions, fractions eluted in 400 mM imida-

zole were pooled and concentrated to a volume of less than
250 L using an Amicon Ultracel-3K centrifugal filter unit
(Millipore). The concentrated protein fraction was then injected into an AKTA FPLC and resolved on a Superdex
75 gel filtration column (GE Healthcare) in 20 mM sodium
phosphate pH 8.0, 300 mM NaCl, 50 mM potassium glutamate (KC5 H8 NO4 ) and 5 mM 2-mercaptoethanol. The
eluted fractions were then pooled and concentrated using
an Amicon Ultracel-3K centrifugal filter unit (Millipore).
All isotopes were purchased from Cambridge Isotopes Laboratories.
Next generation sequencing of MLV IN C-terminal truncations
Sequencing was performed exactly as described before (5).
Analysis of integration sites near Brd2, 3 and 4 binding
sites were correlated using ChIP-seq data (19) and analyzed
as described previously (8). The statistical test rely on the
variance-covariance matrix of the relative ranks of the integration sites to construct Wald-type test statistics and referred to the Chi Square distribution to obtain P values
(20). Datasets used in the analysis: the inset box defines
the data sets used in the analysis; FV fibroblast (21), HIV1 (22), MLV ((5) and this work), WT MLV IN1–408 , MLV
IN1–385 8N , MLV IN1–385 16H , MLV IN1–385 XN (in6215a (11),
(Supplementary Table S4).
NMR analysis of MLV CTD structure and ET interactions
Single- (15 N) and double-(13 C, 15 N) enriched MLV IN CTD
protein samples for studies of complex formation were concentrated to approximately 200 M–1 mM concentration
and where indicated, mixed with 2 mM unlabeled Brd3 ET
in a buffer containing 5% 2 H2 O, 50 mM DSS, 300 mM
NaCl, 50 mM potassium glutamate, 25 mM sodium phosphate at pH 7.0 or pH 8.0 and 5 mM 2-mercaptoethanol.
Samples for NMR studies at pH 6.5 were prepared as described for pH 8.0, except at 100 mM NaCl and in the
absence of 2-mercaptoethanol. Sequence-specific backbone
1
H, 13 C and 15 N resonance assignments for free and ETbound IN329–408 were determined at pH 7.0 and 8.0 using standard triple NMR resonance experiments (23). Resonance assignments and the solution NMR structure determination of IN329–408 at pH 6.5 are reported elsewhere
(PDB ID: 2M9U, BMRB ID: 19299). All spectra were
recorded using a Bruker Avance 800 MHz spectrometer at
25◦ C. NMR data were processed using NMRPipe (24) and
SPARKY (T. D. Goddard and D. G. Kneller, SPARKY 3,
University of California, San Francisco). The oligomeric
states of both free and complexed proteins (1:1 molar ratio of IN CTD:Brd3 ET at 100 M or 200 M) were
assessed by measurements of rotational correlation times
computed from 15 N T1 and T2 nuclear relaxation measurements, as described previously (25–26). Detailed protocols
and calibration data for molecular correlation time measurements based on 15 N nuclear relaxation rate data are
provided online at (http://www.nmr2.buffalo.edu/nesg.wiki/
Main Page). Peptides used for the TP competition assay
are ‘WT TP’––SRLTWRVQRSQNPLKIRLTREAP; and
‘mutant TP’––SRLTARVQRSQNAAAIALTREAP (Pep-
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tide 2.0 Inc.). The peptides were solubilized in deionized
water to a final concentration of about 3 mM.
In vitro pull down assays
Pull-down assays were performed as described (8).
Protein interaction trap assay
The protein interaction trap assay (27) was adapted and performed as described in Supplementary Data.
Data deposition
The sequences reported in this paper have been deposited in the National Center for Biotechnology Information Sequence Read Archive (project accession number
SRP021184).
RESULTS
The structure of the MLV IN CTD changes in the presence
of the Brd3 ET domain
The MLV IN interacts through its CTD with the BET family members through the ET domain (8). We have determined the three-dimensional structure of the MLV IN CTD
(28) (PDB ID 2M9U) using conventional triple-resonance
solution-state NMR methods. It consists of an SH3 fold followed by a long unstructured tail (Figure 1A, B and C).
The solution structure and NMR resonance assignments
(BMRB ID 19299) of the IN CTD provide unique tools to
characterize IN-BET protein interactions.
Changes in the structural environment of amino-acid
residues within the IN CTD upon complex formation with
the ET domain of the BET protein can be monitored using
the chemical shifts of backbone and side chain NMR resonances. Changes include both chemical shift changes, and
changes in amide 1 H resonance intensities due to altered
exchange rates with solvent water protons. Both of these effects upon complex formation are referred to in this study
as chemical shift perturbations (CSPs). Using standard 2D
[15 N-1 H]-heteronuclear single quantum coherence (HSQC)type NMR experiments, backbone amide, side chain amide,
arginine guanido and tryptophan indole 15 N-1 H NMR resonances can be monitored. Changes in 15 N and/or 1 H resonance frequencies and/or intensities can arise from many
different aspects of the complex formation, including interfacial interactions, disorder to order transitions and/or
occlusion of amide protons from solvent exchange due to
formation of protein-protein interfaces or ordered structure
within the TP region. In the case of complex formation between the IN CTD and BET ET domains, the TP region of
the CTD becomes ordered in the complex and CSPs arise
from both this change in the structure of the TP region and
the specific interactions of the intermolecular interface.
Using standard [15 N-1 H]-HSQC experiments at 600
MHz, IN CTD-Brd3 ET interactions could be detected at
pH ≥ 7.0, but not at pH 6.5 that was used to solve the solution NMR structure of the IN CTD (28). Accordingly,
backbone 15 N, 1 H and 13 C resonance assignments for IN

CTD, with and without complex formation with the unlabeled Brd3 ET domain, were redetermined at pH 7.0 and
pH 8.0 using standard triple-resonance NMR experiments
(23). Tryptophan indole N⑀H resonances appearing in the
[15 N-1 H]-HSQC spectra were also assigned. These NH resonance assignments are tabulated in Supplementary Table
S1.
In transitioning from pH 6.5 to pH 8.0, the HSQC spectra of the free CTD domain exhibit attenuation of surface
amide proton intensities due to base-catalyzed amide proton exchange. This attenuation of amide proton intensities
is illustrated in Supplementary Figure S1A and B. However,
in the spectra of the complex formed between 15 N-enriched
IN CTD and unlabeled Brd3 ET domains, many of these
same amide sites do not exhibit attenuation due to solventexchange broadening. This is because they are occluded due
to structure formation in the TP region and/or due to the
interface formed with the ET domain.
Figure 1 documents the significant NH CSPs, including
changes in both frequencies and intensities of resonances,
of IN CTD due to complex formation with Brd3 ET. Overlaying the [15 N-1 H]-HSQC spectra at pH 8.0 for the IN
CTD in the presence (Figure 1D, blue) and absence (Figure 1D, red) of Brd3 ET demonstrates that binding of the
Brd3 ET domain protects specific amide resonances from
solvent-exchange broadening typical of surface amide NH
resonances at pH 8.0. Significant resonance frequency shifts
as large as 0.5 ppm are observed for the NH resonances of
R391, V392, Q393, R394, L399, K400, I401, R402, L403
and T404 (Figure 1D and Supplementary Figure S1A and
B). In addition, tryptophan indole N⑀H resonances for
residues W347, W369 and W390 appear or shift in the presence of Brd3 ET. Other amide resonances altered in intensity and/or frequency upon complex formation with Brd3
ET include residues Q339 and L343 (Figure 1A, in ß1–ß2
loop), T359 (Figure 1A, in ß2–ß3 loop), G365 (Figure 1A,
in ß3–ß4 loop) and G381–383, R387, L388, T389, W390,
S395, N397, R405, E406 and A407 (Figure 1A, C-terminal
region). Several of these TP-associated NH resonances are
observed in the complex but not in the free CTD at pH 8
(Figure 1D and Supplementary Figure S1B). Significantly,
at pH 6.5, these resonances have amide 1 H chemical shifts
typical of disordered polypeptide segments (i.e., in the range
of 7.5–8.5 ppm; Supplementary Figure S1A).
Figure 1B and C shows a representation of the sites in
the IN CTD domain that are perturbed in the presence
of Brd3 ET mapped onto the 3D structure characterized
at pH 6.5. The core ␤-barrel of the SH3 fold of the IN
CTD is not affected by complex formation with the Brd3
ET. Rather, 22 of the 25 non-proline residues whose amide
resonances exhibit significant CSPs (i.e., either slowed in
solvent exchange and/or altered in chemical shift) are localized in the TP region, C-terminal to the SH3 fold. This
suggests that the heterodimeric interaction is facilitated primarily through residues localized in the disordered TP region, many of which are conserved in other INs of the gammaretroviral genera (Supplementary Figure S1C).
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Figure 1. NMR analysis of MLV IN: Brd3 ET interaction. A. MLV IN CTD sequence is displayed with the following color codes: green indicates backbone
amide resonance chemical shifts that were the same for IN CTD in the presence or absence of Brd3 ET at pH 8.0; red indicates backbone amide resonances
that are observed in the presence of Brd3 ET, but solvent exchange broadened in the absence of complex formation, and/or amide resonances that exhibit
frequency shifts upon complex formation; blue indicates backbone amide resonance assignments that could not be determined at pH 8.0 either in the
presence or absence of the Brd3 ET domain. Residues for which HN amide assignments could not be determined in either free or ET-bound CTD at pH
8.0 include R337, H338, T340, K341, N342, R346, W347, A367, S385, S386, Q396, as well as proline residues P345, P350, P358, P380, P384, P398 and
P408 which lack amide protons. B. C␣ backbone trace, along with key structural features, of an ensemble of 20 conformers of MLV IN CTD from amino
acids 329–408 (PDB ID 2M9U) is shown in this panel with the same color codes as described in panel A. C. Ribbon representation of a single MLV IN
CTD conformer is shown within a transparent view of a surface space fill model. Color code is the same as in panel A with key structural features and
specific amino-acid residues that show significant CSPs and/or reduced amide proton exchange broadening marked in red. All images were generated
using PyMol (The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC.) D. NMR spectrum of the IN CTD–Brd3 ET complex.
Overlay of [15 N−1 H]-HSQC spectra of 15 N-enriched IN CTD construct IN329–408 at pH 8.0, 300 mM NaCl either with (blue) or without (red) unlabeled
Brd3ET. The stoichiometric ratio of IN329–408 (1 mM) and Brd3 ET (2 mM) was 1:2 at the concentrations indicated. Backbone amide resonances that
are not affected by complex formation are labeled with sequence-specific assignments in black; assigned amide resonances that are not observable due to
solvent-exchange broadening in the absence of ET, but become observable upon complex formation, as well as resonances exhibiting significant CSPs upon
complex formation are labeled in magenta. All amide peak resonances not observable due to solvent-exchange broadening in the absence of ET, but become
observable upon complex formation are marked with black circles; some of these could not be unambiguously assigned at pH 8.0. The curved green arrows
indicate the CSPs due to complex formation of the amide resonances assigned to residues L399, L403, A407 and the side-chain indole NH⑀ resonance of
W390. Tryptophan W347 and W369 NH⑀ side chain indole resonances with significant proton exchange rate reduction due to complex formation are also
indicated. Peak resonances labeled in green are assigned to the non-cleavable affinity tag.
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Figure 2. MLV IN interacts with the BET family through the IN TP. A.
Rotational correlation time measurements. Plot of rotational correlation
time ( c ) computed from 15 N T1 /T2 relaxation rate measurements versus
molecular weight. Known monomeric protein standards are indicated in
red. Data for the three IN CTD constructs (IN329–408 , IN329–385 XN and
IN329–385 ) are indicated in blue (individually) and green (in the presence
of the Brd3 ET domain). The molar ratio of the IN CTD constructs and
Brd3 ET proteins was 1:1 at 100 M. Plots of the 15 N T1 and T2 nuclear
relaxation data for each sample are presented in Supplementary Figure
S2. B. Interaction of MLV IN TP with Brd4. GST pull-down experiments
performed with WT GST-MLV IN1–408 and IN C construct GST-MLV
IN1–385 with Brd41–720 . Coomassie stain of SDS/PAG of GST pull-down
products. Components of individual reactions are indicated as well as 10%
of the purified Brd41–720 input sample. The predicted molecular of the
GST-MLV IN1–408 fusion protein is 69 kDa. Positions of molecular weight
standards are indicated on the left.

The absence of the IN CTD TP disrupts the heterodimeric
interaction
Having established that the heterodimeric IN CTD-Brd3
ET interaction is facilitated primarily by residues in the
TP that are largely disordered in the IN free CTD (28),
we next explored the impact of truncating these disordered
residues on complex formation. Molecular rotational correlation time ( c ) measurements, based on simple 1D 15 N
nuclear relaxation rate measurements, can be used to estimate molecular mass changes upon complex formation under precisely defined conditions (25). These data are summarized in Figure 2A with supporting data in Supplementary Figure S2. A calibrated plot of  c versus molecular
weight (Figure 2A) indicates that at 100 M concentration, 300 mM NaCl, pH 8.0 and 25◦ C, MLV CTD construct IN329–408 behaves as a monomer ( c = 6.6 ns, MW
∼ 10.5 kDa). Addition of stoichiometric amounts of unlabeled Brd3 ET results in a heterodimer ( c = 10.9 ns, MW ∼
18 kDa). Two MLV IN CTD constructs truncated at the Cterminus (C), IN329–385 and IN329–385 XN were also found
to behave as monomers in either the presence or absence of
unlabeled Brd3 ET (i.e.,  c = 4.5 - 6.1 ns, MW ∼ 8 ± 1 kDa),

as illustrated in Figure 2A. Under these conditions, removal
of the IN TP prevents heterodimer formation.
In order to validate that the truncation of the TP region
did not affect the 3D structure of the rest of the IN CTD, we
also recorded [15 N-1 H]-HMQC NMR spectra of the IN C
constructs (Supplementary Figure S3). These data demonstrate that truncation of the C-terminal disordered TP region does not affect the 3D structure of the rest of the
CTD domain, including the core SH3 fold. The activity of
IN constructs truncated at residue 385 has been extensively
characterized in vitro and in vivo (11–14,29–30. Additional
characterization with respect to viral titer, reverse transcriptase activity, minus-strand strong stop and plus-strand extension, Alu-PCR and two-end integration assays are described in the Supplementary Data.
These NMR studies of the IN CTD in the presence
of the Brd3 ET domain provide biophysical evidence of
the two proteins interacting, with changes in the MLV IN
CTD NMR spectra clustering within the disordered IN Cterminal TP. The interaction with the Brd3 ET domain requires the C-terminal polypeptide region, and is suppressed
by deletion of residues 386–408.
Additional protein interaction studies corroborate the
role of the TP region in the structural basis of Brd3 ET
binding. Figure 2B and Supplementary Figure S4 document direct binding between GST-MLV IN1–408 and fulllength Brd2, Brd3 and Brd4 constructs. This interaction
was lost with constructs lacking the CTD TP (e.g., GSTMLV IN1–385 in Figure 2B and Supplementary Figure S4).
Yeast two-hybrid studies were also used to analyze the interaction between the mouse Brd2 ET domain and Moloney
MLV (M-MLV) IN (mIN1–408 ) (Table 1). The interaction
between the LexA-mIN bait plasmid and the GAL4-ET
domain prey plasmid in the colony lift assay was readily
detected, as indicated by the blue color observed in the
␤-galactosidase assays. This interaction was stronger than
the dimerization between M-MLV IN monomers (pSH2mIN plus pGADNOT-mIN or pACT2-mIN). Deletion of
the MLV IN C-terminal TP (pSH2-mIN1–385 XN ; IN C),
markedly decreased the interaction with the Brd2 ET domain (pACT2-Brd2 ET; Table 1). Negative controls remained white, other than a very weak background interaction observed between the MLV IN expression construct
(pGADNOT-5’mIN) and the empty vector (pSH2–1). Proteins expressing the HIV-1 p66 and p51 reverse transcriptase
subunits (pSH2-p66 and pGADNOT-p51) served as positive controls.
Taken together, the protein interaction data summarized
in Figure 2, Table 1 and Supplementary Figures S3 and S4
unequivocally demonstrate that the TP region of MLV IN,
including residues 386–408, is critical for interactions with
the ET domains of Brd2, Brd3 and Brd4 BET family members.
TP competition assay shows sequence-dependent disruption
of the heterodimeric interaction
The importance of the TP region was further validated using a 24 amino-acid peptide (WT TP; Figure 3A) in a competition assay to disrupt the MLV IN CTD and Brd3 ET
complex. The TP region contains a 390 WX7 PLKI /L R402
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Table 1. Interaction between M-MLV IN and Brd2 ET LexA DNA binding domain fusions
GAL4 AD Fusions

pSH2-1

pSH2-p66

pSH2-mIN1––408

pSH2-mIN1–385 XN

pACT2-empty
pACT2-mIN
pACT2-Brd2-ET
pGADNOT-empty
pGADNOT-p51
pGADNOT-mIN
pGADNOT-5’mIN
pGADNOT- Ddxp18

−
−
−
−
−
−
+/−
−

−
−
nd
−
+++
−
−
nd

−
+/−
+++
−
−
+/−
+
++

−
+
+
−
−
+
++
++

Qualitative ß-galactosidase yeast colony lift assays. Results represent the average colorimetric values from six independent transformation reactions and
their corresponding ß-galactosidase assays. p51 and p66 represent the components of the HIV-1 reverse transcriptase heterodimer. The LexA DBD bait
vectors are pSH2 and its derivatives; the GAL4-AD vectors pACT2 and pGADNOT (or their derivatives) are the prey vectors. Ddxp18 was previously
isolated as an IN interactor in a yeast-two hybrid screen (27). Interaction key: (–) white; (+/–) pale blue; (+) light blue; (++) intermediate blue; (+++) dark
blue; (nd) not determined (27).

motif that is conserved across gammaretroviral IN proteins
(Supplementary Figure S1C). Accordingly, in addition to
the wild-type (WT) peptide, a second 24-residue mutant TP
in which all five of the conserved amino acids in the consensus motif are replaced with alanine (Figure 3A) was also
studied.
Rotational time ( c ) measurements, summarized in Supplementary Table S2 and supported by data in Supplementary Figure S5, demonstrate that the 24-residue WT TP disrupts the heterodimeric IN CTD–Brd3 ET complex. [15 N1
H]-HSQC spectra presented in Figure 3B further demonstrate that the WT TP disrupts the complex formed between 15 N-enriched IN CTD (construct IN329–408 ) and Brd3
ET. Adding the WT TP peptide to the complex of 15 Nenriched IN CTD bound to unenriched Brd3 ET dramatically changes the spectrum, resulting in an [15 N-1 H]-HSQC
similar to that of the free full-length IN CTD. The spectrum
of 15 N-enriched IN CTD in the presence of unenriched ET
and WT TP is shown superimposed on the spectrum of free
IN CTD in Figure 3B. The mutant TP, replacing five key
residues with alanine, does not disrupt the complex between
IN CTD (construct IN329–408 ) and Brd3 ET (Figure 3C),
that is, the spectrum of the complex is not altered by adding
the mutant TP peptide. These data demonstrate the importance of some or all of these five residues in the energetics
of complex formation.

Truncation of the CTD C-terminal TP results in decreased
integration at TSS and CpG islands.
A hallmark of MLV integration is the preferential integration within 2 kb of TSS and CpG islands (Figure 4A and B).
The down regulation and inhibition of BET proteins have
been shown to influence this integration bias. The BET protein inhibitor JQ1 blocks binding of BET proteins to modified histones but maintains the interaction of BET proteins
with IN. Truncation of the MLV IN CTD rather resulted
in the direct loss of interaction with BET family members
(Figure 2, Supplementary Figure S4 and Table 1). Mapping the integration site profile for MLV lacking the IN Cterminal TP thus tests whether the binding of BET family
proteins drives MLV integration to TSS and CpG islands
and presents a direct mechanism to alter the MLV integration preference.

Viruses lacking the C-terminal TP (C) are viable in tissue culture and multiple tags have been inserted into the Cterminal segment of MLV IN (11,12,30–31). The integration target-site distribution of three constructs lacking the
C-terminal 23 amino acids of IN were examined (IN1–385 XN
(in6215a) (11)), IN1–385 8N and IN1–385 16H ) each differing in
the non-viral amino-acid sequence tags at their terminus
(Supplementary Data). Viral titers were within 2–4-fold of
WT for all three IN C virus (Supplementary Table S3) and
cells transfected with all three IN C constructs were positive for reverse transcriptase by the end of the second passage of cells (day 8 post transfection; Supplementary Figure S6A). Additionally, accumulation of reverse transcription intermediates and the copy number of viral integrants
of the IN C constructs were within 2-fold of WT MLV
(Supplementary Figure S6B and C). All three MLV IN C
constructs showed markedly diminished preference for integration at TSS (Figure 4A, red arrow) and CpG islands
(Figure 4B, red arrow) compared to the experimental WT
MLV IN control and a compilation of published MLV integration sites generated by infection of 293T cells (Supplementary Table S4). For example, integration of IN C constructs plus or minus 1 kb of TSS averaged ∼2.5% of the
total integrants, whereas ∼12% of the WT MLV mapped
within this interval. Levels of the MLV IN C constructs
remained above the published levels for the Foamy virus
and HIV-1 integrants in 293 and 293T (Figure 4 and Supplementary Table S4). Loss of localization to TSS and CpG
islands was not specific for oncogenes; analysis of housekeeping genes showed a similar decrease in targeting their
promoter regions (Supplementary Figure S7). Analysis of
the local sequence bias at the site of the target DNA duplication revealed that the IN C constructs maintained
the characteristic palindromic consensus sequence of MLV
(Supplementary Figure S8) at the scissile bonds (32). These
results indicate that the loss of the IN C-terminal TP, which
is the key IN:BET interaction domain, results in redistribution of viral integration sites away from promoter regions
without grossly altering virus viability (11).
MLV IN C integration sites lose association with known
BET protein binding sites in 293 cells
In 293 cells, binding sites of BET proteins (Brd2, Brd3 and
Brd4) have been identified by chromatin immunoprecipita-
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tion and mapped onto the human genome (19). The correlation of these BET protein binding sites and integration sites
of MLV WT IN and IN C viruses was examined (Figure
4C). Analysis was performed using the total BET protein
binding sites (Figure 4C: promoters + within genes + intergenic regions) and as well as those limited to specific promoter regions (Figure 4D). WT IN integrations correlated
with identified Brd2, Brd3 and Brd4 binding sites compared
to matched random controls throughout the host chromosomes. Integrants obtained from all three IN C isolates
showed a marked decrease (∼2-fold, P < 0.001) compared
to the WT IN integrants. Interestingly, this effect was localized to within 100 bp of a known BET protein-binding site.
Approximately 9–13% of BET protein binding sites map
within 2 kb of genes (19). Analysis of the MLV integrants
from IN C isolates indicated a more pronounced decrease
in association with BET protein binding sites (4-fold) located within promoters upon loss of the IN C-terminal TP
(Figure 4D), mapping to within 100 bp of the identified
Brd2, Brd3 or Brd4 sites. These results indicate that the loss
of the IN C-terminal tail results in the loss of targeting to
identified binding sites of BET proteins.
DISCUSSION

Figure 3. Mutating the consensus TP sequence inhibits interaction of
MLV IN CTD with Brd3 ET. A. The 24-residue WT TP sequence is displayed on top and the mutant TP sequence is displayed on bottom. Underlined residues indicate amino-acid residues mutated to alanine. B. Comparison of [15 N-1 H]-HSQC spectra of the complex formed between 15 Nenriched IN CTD (construct IN329–408 ) and unlabeled Brd3 ET in the
presence of the WT TP (blue) and the free 15 N-enriched IN CTD (construct IN329–408 ) spectra (red; same as Supplementary Figure S1B). The
stoichiometric ratio of IN329–408 (200 M) and Brd3 ET (200 M) was
1:1 and the peptide was added at 3-fold molar excess (600 M). Under
these conditions, the WT TP disrupts the complex by binding to the ET
domain, resulting in a spectrum for CTD that is different from that of
the complex, but essentially identical to that of free IN CTD. C. Comparison of [15 N-1 H]-HSQC spectra of 15 N-enriched IN CTD (construct
IN329–408 ) and unlabeled Brd3 ET in the presence (red) or absence (blue)
of the mutant TP. The stoichiometric ratio of IN329–408 (200 M) and Brd3
ET (200 M) was 1:1 and the mutant peptide was added at 3-fold excess
(600 M). The mutant TP does not disrupt the complex, and the spectrum is not changed when the peptide is added. In both panels, backbone
amide resonances are labeled in black and peak resonances labeled in magenta are assigned to the non-cleavable affinity tag. Buffer conditions are
as follows––buffer 1: 25 mM sodium phosphate pH 8.0, 300 mM NaCl,
50 mM potassium glutamate, 5 mM 2-mercaptoethanol. Buffer 2: 25 mM
sodium phosphate pH 8.0, 360 mM NaCl, 60 mM potassium glutamate, 6
mM 2-mercaptoethanol.

The results of this study establish the molecular mechanism
of MLV retroviral integration into TSS and CpG islands
by tethering MLV IN with BET family proteins Brd2, Brd3
and Brd4 (Figure 5). Using solution NMR and biochemical studies, the interaction was localized predominantly to
the C-terminal polypeptide tail segment of the MLV IN
protein, including residues 386–408. In the absence of the
BET proteins, the MLV IN C-terminal peptide (TP) is unstructured. It becomes structured upon complex formation
with the Brd3 ET domain. This disorder-to-order transition may contribute a significant entropic component to the
energetics of complex formation. The TP is non-essential
for virus viability; however, viruses lacking the TP show
marked diminution of integrations at the TSS and CpG islands, which are favored targets of MLV DNA integration
in chromosomes. Loss of the MLV IN TP also correlated
with the loss of association with BET protein binding sites
within 293 cells.
Backbone CSPs upon complex formation indicate a
change in the environment of the corresponding backbone
atoms. Such changes implicate the corresponding region of
the polypeptide or protein in the molecular recognition process, but do not necessarily demonstrate a direct contact of
the corresponding residue in the intermolecular interface;
that is, CSPs do not necessarily indicate direct intermolecular interactions. Site directed mutations could be used to
validate the role of specific atoms in interfacial interactions,
but the interpretation of such data requires structural data
demonstrating that such sequence changes do not disrupt
the structure of the CTD or the CTD–ET complex distal
from the site of mutation. In any case, the extensive CSP
data for free and ET-bound IN CTD, summarized in Figure 1 and Supplementary Table S1, provide unequivocal evidence for structural changes in C-terminal TP region of IN
CTD upon complex formation, providing a structural basis
for the interaction between these two domains.
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Figure 4. MLV IN C integrations lose association with TSS, CpG islands and known BET protein binding sites in 293 cells. A. Percentages of integration
sites in 293 cells are plotted with respect to the distance from the annotated TSS compared to matched random controls (MRCs) (50). B. Percentages of
integration sites are plotted with respect to the distance from the 5’ end of the nearest CpG islands compared to MRCs. C. Total BET binding sites in 293
cells. Integration sites were measured for its proximity to the 5’ boundary of known BET protein binding sites compared to MRCs. MRCs are selected
randomly from the host genome respective to a restriction site and should have no relation to chromatin sites. D. BET protein chromatin binding sites that
overlap with promoters as defined in LeRoy et al. ((19); additional file 8). Loss of association of the IN C versus the WT IN within 100 bp of chromatin
sites bound by BET proteins was statistically different with P < 0.001 for both the total BET sites and those localized to specific promoters, respectively.
Square bracket denotes inclusion of the limit, while parenthesis denotes exclusion.

The C-terminus of MLV IN is non-essential for IN enzymatic activity in vitro (13) and for virus viability in tissue culture (12,31), however second-site revertants have been isolated from modified IN C virus where the IN C-terminal
tail was restored (31). The MLV IN TP overlaps with the
Env signal peptide in an alternative reading frame. The sequence conservation within the IN TP/4070A amphotropic

Env overlap region displays a bias toward maintenance of
the IN reading frame (33). This suggests that the C-terminal
segment of IN may have a functional role in vivo. Alignment of retroviral IN proteins with known targeting to
TSS and CpG islands show conservation of the sequence
390 WRVQRSQNPLKIRLTR405 located at the MLV IN Cterminus (Supplementary Figure S1C). This homology ex-
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Figure 5. Model for MLV integration. A. Assembly of BET proteins on acetylated histone tail (blue) in the presence of additional host factors and RNA
Pol II (together marked as X) to TSS. MLV IN interacts with the ET domain of BET proteins through the IN TP (red) resulting in a preponderance of
integrations near TSS. B. Loss of MLV IN TP results in loss of association with BET proteins and results in decreased targeting to BET binding sites and
TSS.

tended to the core consensus of 390 WX7 PLKJR402 (Figure
S1C; J = I/L) in RaLV, GaLV and KoRV, but the integration site preferences for these viruses have not been analyzed. It is predicted that these would be critical for the
interaction with BET family members. Indeed, the peptide
competition assay (Figure 3 and Supplementary Table S2)
shows that one or more of residues W390, P398, L399, K400
and R402 contribute to the energetics of complex formation. Additionally, IN W390A has been shown to have reduced binding affinity for Brd4 ET (10).
The function of the IN C-terminal tail appears analogous to that of the histone (34–35) and RNA polymerase
II tails (36), as an otherwise unstructured docking site for
additional proteins or regulatory factors (Figure 5). Interestingly, the NS1 protein of influenza A H3N2 subtype is
proposed to use a related histone mimic as a means to associate with the human PAF1 transcription elongation complex and thus inhibit the antiviral response (37).
Targeting of IN integration to active promoter regions
is beneficial for expression of the viral genome for subsequent rounds of infection. However, targeting to promoter
regions only accounts for approximately 25% of all MLV
retroviral integrations. Loss of targeting through the BET
proteins does not affect the majority of MLV integration
events. The local sequence selection at the site of integration
(LOGOs analysis) remain unchanged in the absence of the
IN TP. The quantitation of integration copy numbers of the
three replicating IN C isolates was statistically similar to
WT IN and consistent with the 2-fold variation observed for
a single round of infection (12). Additionally, reverse transcription of the viral genome into dsDNA is not grossly affected by the absence of the IN TP (Supplementary Figure
S6B and C). Variations in viral titers (between 2- and 4-fold)
and the time course of viral spread were observed between

the three IN C isolates. These assays depend on the level
of expression of the viral or transgene mRNA. Loss of targeting to highly expressed promoter regions can result in a
decrease in the total level of viral mRNA produced and thus
be reflected in minor variations in viral titer and subsequent
proviral integrations. Alternatively, the differences in the IN
terminal amino acids may affect the association with other
unidentified host factors.
Recently, it was reported that three residues in the MLV
IN CCD are important in the interaction with BET proteins
(9). It is unclear whether these mutations compromise MLV
IN catalytic activities or indirectly affect interactions with
BET proteins. Despite an intact TP region, interaction with
BET proteins was lost in the context of these CCD mutations. It is possible that the presence of a C-terminal FLAG
tag used in that study might compromise the binding potential of the TP region. Loss of the IN TP though did not
compromise IN catalytic activities within the CCD or those
requiring multimerization including two-end concerted integration (Supplementary Figure S9).
Interestingly, BET family members have been implicated
in other viral systems and used to regulate viral transcription as well as tethering the viral DNA complexes to mitotic chromosomes. Both the KSHV LANA protein and
the Merkel cell polyomavirus T antigen bind Brd4 through
protein–protein interactions with the ET domain (38–40).
In addition, various animal and human papilloma viruses
interact with the host protein Brd4 (41). For MLV, integration at BET protein binding sites positions the virus within
transcriptionally active regions of the host chromosomes
and should facilitate viral gene expression.
Multiple retroviral and retrotransposon systems utilize
host proteins to influence their position of viral integration.
Integration of HIV-1 is directed within genes through asso-
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ciation with the host factor LEDGF/p75 (22,42–44). Yeast
Ty1 and Ty3 target integration into tRNA genes. Ty3 interacts with Brf1, TFIIB and TBP, which are involved in Pol III
transcription (45). Recent studies of Ty1 targeting to tRNA
genes implicate a possible histone modification near Pol III
transcription sites as a driving factor for recognition (46).
For Tf1, it is known that a chromodomain at the C-terminus
interacts with the host Atf1 protein to drive integration into
genes associated with environmental stresses (47).
The function of the ET domain of BET family members
is not well defined. Recent studies have identified NSD3,
JMJD6, CHD4, GLTSCR1 and ATAD5 proteins as binding partners to the BET family members ET domain (48)
and thus the ET domain functions to recruit specific effector
proteins to regulate transcriptional activity. It is not known
if binding of the MLV IN TP interferes with the function of
the ET domain and/or the association of cellular proteins
to this domain. The solution structure of the Brd4 ET domain consists of three ␣-helices plus a loop structure, with
no close structural homologs (49). Binding to IN is localized to the acidic patch in the ␣2–␣3 loop region (9–10).
The solution structure of the ET domain:IN CTD complex
will be interesting to elucidate.
Mapping of WT integrated MLV proviruses shows favored targeting within 2 kb of the TSS and CpG islands (3).
For the WT IN, correlation with the chromatin binding sites
of BET proteins showed a tighter association, favoring integration within 100 bp of the defined BET protein binding
sites for Brd2, 3 and 4. The two analyses measure distinct
features, as the positions of the BET sites with respect to
the TSS are not defined. Loss of the IN TP did not affect
a panel of additional features, including integration in gene
dense regions (50). MLV integrants are reported to be associated with the supermarkers (51) containing H3K4me1,
H3K4me3, H3K9ac chromatin marks and STAT1 binding
sites. Indeed, comparison of the integration sites of the WT
IN versus the IN C constructs from this study with the
epigenetic maps of HeLa and resting T cells correlated the
loss of the IN TP with the loss of integrants at H3K4me1,
H3K4me3, H3K9ac chromatin marks, STAT1 binding sites
and H2AZ sites (data not shown). Understanding the additional proteins that assemble with the preintegration:BET
complexes will shed light on the molecular mechanisms
associated with recognizing these supermarkers as well as
those that stabilize gene or promoter-specific targets. This
knowledge has direct implications for understanding the
potential of murine-based vectors for gene activation resulting from insertional viral mutagenesis.
Eliminating the interactions with BET family members
has implications for the use of gammaretroviral vectors for
gene therapy and gene delivery. Foamy viruses, which have
limited bias to integrate at TSS and CpG islands have been
shown to be apathogenic in humans (52). Vectors lacking the IN TP would decrease targeting to promoter regions of all classes of genes, not specifically oncogenes. This
nonetheless has the potential to decrease the probability of
promoter/enhancer insertional mutagenesis due to viral integration at promoter regions. The modulation of overall
expression of the transgene due to chromosomal positional
effects might become more evident in the absence of BET
protein targeting. Current studies are aimed at defining the

potential of oncogene activation resulting from integration
of MLV bearing the IN C proteins.
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